Home Overview Press Room Blog Publications For Students about us
Search

Sequencing & Genomics : Displaying 330-339 of 1106


The $1,000 Genome: Game Changer or PR Stunt?by Jessica CussinsBiopolitical TimesFebruary 6th, 2014The DNA sequencing company Illumina announced a new product capable of sequencing an entire human genome for under $1,000. What are the hidden costs? What are the implications of reaching this long-awaited benchmark?
Genetics for the People?by Donna DickensonProject SyndicateFebruary 5th, 2014The rhetoric of personal ownership and control touted by 23andMe hides their flimsy data and actual business plan.
Ethics Questions Arise as Genetic Testing of Embryos Increasesby Gina KolataThe New York TimesFebruary 3rd, 2014The procedure raises unsettling ethical questions that trouble advocates for the disabled and have left some doctors struggling with what they should tell their patients.
On Race and Medicineby Keith NorrisThe ScientistFebruary 1st, 2014While age and gender are strongly associated with biological differences that may have a significant impact on disease susceptibility and treatment response, the role of race/ethnicity is far less clear.
Why we Should Opt Out of the Government's New Patient Databaseby Edward HockingsThe GuardianJanuary 31st, 2014Medical records in England and Wales will soon be linked to whole-sequenced genomes. Choosing to "opt out" is also taking a stand on what kind of society we want in the future.
Genetic Determinism: Why we Never Learn — And Why it Mattersby Nathaniel ComfortGenotopiaJanuary 29th, 2014Studying the history of genetics and popularization has led me to the surprising conclusion that genetic oversell is independent of genetic knowledge. We see the same sorts of articles in 2014 as we saw in 1914.
How FDA and 23andMe Dance Around Evidence That Is Not Thereby Cecile JanssensHuffington PostJanuary 27th, 2014Almost all former direct-to-consumer genetic testing companies have closed up shop. In the wake of criticism from all sides will 23andMe be next?
Right on target: New era of fast genetic engineeringby Colin BarrasNew ScientistJanuary 27th, 2014If we ever decide to genetically modify people, this is the tool to do it with.
California’s stem cell agency poised to bet big on genomics researchby David JensenSacramento BeeJanuary 26th, 2014Directors of the California stem cell agency are preparing to create one or two stem cell genomic centers that they predict will make the state a world leader in the new field.
A genetic “Minority Report”: How corporate DNA testing could put us at riskby Benjamin WinterhalterSalonJanuary 26th, 201423andMe's FDA problems are just the beginning - the company's DNA tests open up a wealth of privacy concerns.
Displaying 330-339 of 1106  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760